Padagis Announces New CEO: Pamela Hoffman Takes the Helm for Expansion

Padagis Appoints Pamela Hoffman as Chief Executive Officer

In a significant move for the pharmaceutical landscape, Padagis announced on April 1, 2026, that Pamela Hoffman has been appointed as the new Chief Executive Officer. With over twenty years of invaluable experience in the industry, Hoffman is stepping into a pivotal role at the helm of the company, which she joined during its inception in 2021.

Prior to her promotion to CEO, Hoffman served as the Chief Financial Officer and later as President, demonstrating her leadership capabilities and dedication to Padagis. During her tenure, she was instrumental in navigating critical achievements for the organization, including its successful separation from Perrigo, the introduction of OTC Naloxone, and the expansion of the company's manufacturing capabilities.

As she assumes the role of CEO, Hoffman is poised to oversee all operations and strategic initiatives aimed at expanding Padagis' footprint within the U.S. specialty generics market. Her focus will remain on ensuring that the company continues its mission to provide patients with accessible and cost-effective treatment options.

"Padagis has built a strong foundation delivering high-quality, affordable medications to patients and healthcare providers," Hoffman expressed. "I’m honored to take on expanded responsibilities as CEO and to continue working alongside our talented team to strengthen partnerships and advance our mission. We are on the cusp of exciting growth and innovation, and I look forward to what lies ahead."

Padagis, based in Michigan, operates with a steadfast commitment to lowering healthcare costs and enhancing accessibility through innovative strategies. The company has emerged as a key provider of extended topical medications and various specialty drugs, predominantly within the United States. Among its flagship products is Naloxone, a life-saving nasal spray designed to counteract opioid overdoses. The organization is deeply committed to making this medication readily available in efforts to combat the opioid crisis and save lives.

Pamela Hoffman will also be a member of the Padagis Board, bringing her insights to the strategic conversations that shape the company’s direction. Her leadership is widely regarded, particularly by Tim Callahan, Altaris Operating Partner and Padagis Board Compensation Committee Chair. "Pam is a demonstrated leader with deep industry expertise and a strong understanding of the generic pharmaceutical landscape," Callahan noted. "Her leadership has been instrumental in advancing the development of Padagis, and we are excited to partner with her in driving its next stage of growth."

For those interested in following the latest developments at Padagis, further information can be found on their official website www.padagis.com. With Hoffman leading the charge, Padagis is not only looking to broaden its market presence but also to reinforce its dedication to quality healthcare outcomes for all.

As the healthcare sector continues to evolve, Padagis under Pamela Hoffman's leadership represents a beacon of innovation and commitment to improving patient accessibility and affordability in prescription medications. The journey ahead promises to be both challenging and rewarding as they strive to redefine the generics landscape within the pharmaceutical industry.